3'-(9,10-Dioxoanthracen-2-yl)sulfonylspiro[bicyclo[2.2.1]heptane-2,5'-imidazolidine]-2',4'-dione | 1418104-74-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 3'-(9,10-Dioxoanthracen-2-yl)sulfonylspiro[bicyclo[2.2.1]heptane-2,5'-imidazolidine]-2',4'-dione
• 英文别名: 3'-(9,10-dioxoanthracen-2-yl)sulfonylspiro[bicyclo[2.2.1]heptane-2,5'-imidazolidine]-2',4'-dione
• CAS: 1418104-74-1
• 化学式: C₂₃H₁₈N₂O₆S
• 分子量: 450.472
• InChiKey: KWHPTAIZFAUDLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  32
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  9,10-二氧代-9,10-二氢蒽-2-磺酰氯 、 spiro[bicyclo[2.2.1]heptane-2',5'-imidazolidine[2,4]dione] 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以61%的产率得到3'-(9,10-Dioxoanthracen-2-yl)sulfonylspiro[bicyclo[2.2.1]heptane-2,5'-imidazolidine]-2',4'-dione
  参考文献：
  名称：

  Dual action spirobicycloimidazolidine-2,4-diones: Antidiabetic agents and inhibitors of aldose reductase-an enzyme involved in diabetic complications

  摘要：

  The desired 3-(arylsulfonyl) spiroimidazolidine-2,4-diones were synthesized by reacting spiroiminoimidazolidine-2,4-dione with arylsulfonyl chlorides. Spiroimidazolidine-2,4-dione was in turn synthesized from norcamphor. Structures of the synthesized molecules were established by modern spectroscopic techniques. The synthesized compounds were screened for in vivo antidiabetic activity and aldose reductase inhibition. Compounds 2a, 2b and 2g exhibited excellent dual activity, compound 2a being most prominent. These results reveal that the synthesized compounds may serve as the molecule of choice to treat diabetes and diabetic complications using a single medication. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.039

文献信息

• Dual action spirobicycloimidazolidine-2,4-diones: Antidiabetic agents and inhibitors of aldose reductase-an enzyme involved in diabetic complications
  作者：Zafar Iqbal、Sher Ali、Jamshed Iqbal、Qamar Abbas、Irfan Zia Qureshi、Shahid Hameed

  DOI：10.1016/j.bmcl.2012.11.039

  日期：2013.1

  The desired 3-(arylsulfonyl) spiroimidazolidine-2,4-diones were synthesized by reacting spiroiminoimidazolidine-2,4-dione with arylsulfonyl chlorides. Spiroimidazolidine-2,4-dione was in turn synthesized from norcamphor. Structures of the synthesized molecules were established by modern spectroscopic techniques. The synthesized compounds were screened for in vivo antidiabetic activity and aldose reductase inhibition. Compounds 2a, 2b and 2g exhibited excellent dual activity, compound 2a being most prominent. These results reveal that the synthesized compounds may serve as the molecule of choice to treat diabetes and diabetic complications using a single medication. (C) 2012 Elsevier Ltd. All rights reserved.